Literature DB >> 12799792

[Possibilities and limits of immunotherapy in multiple sclerosis. Inflammatory and degenerative aspects of the disease require a new pathogenetic concept].

M E Kornhuber, S Zierz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12799792     DOI： 10.1007/s00115-003-1523-4

Source DB:  PubMed          Journal:  Nervenarzt        ISSN： 0028-2804            Impact factor:   1.214


× No keyword cloud information.
  10 in total

1.  Immunopathology of secondary-progressive multiple sclerosis.

Authors:  J W Prineas; E E Kwon; E S Cho; L R Sharer; M H Barnett; E L Oleszak; B Hoffman; B P Morgan
Journal:  Ann Neurol       Date:  2001-11       Impact factor: 10.422

Review 2.  [MS Therapy Consensus Group. Immunomodulating staged therapy of multiple sclerosis].

Authors: 
Journal:  Nervenarzt       Date:  1999-04       Impact factor: 1.214

3.  Focal encephalitis in the Lewis rat induced by intracerebral enterotoxin superantigen and amplified by activated intravenous splenocytes.

Authors:  Malte E Kornhuber; Caroline Ganz; Roland Lang; Thomas Brill; Wolfgang Schmahl
Journal:  Neurosci Lett       Date:  2002-05-17       Impact factor: 3.046

Review 4.  [Escalating immunomodulatory therapy of multiple sclerosis. 1st supplement: December 2000].

Authors: 
Journal:  Nervenarzt       Date:  2001-02       Impact factor: 1.214

5.  Relapses and progression of disability in multiple sclerosis.

Authors:  C Confavreux; S Vukusic; T Moreau; P Adeleine
Journal:  N Engl J Med       Date:  2000-11-16       Impact factor: 91.245

Review 6.  [Immunomodulatory staged therapy of multiple sclerosis. New aspects and practical applications, March 2002].

Authors:  P Rieckmann; K V Toyka
Journal:  Nervenarzt       Date:  2002-06       Impact factor: 1.214

7.  Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.

Authors:  K P Johnson; B R Brooks; J A Cohen; C C Ford; J Goldstein; R P Lisak; L W Myers; H S Panitch; J W Rose; R B Schiffer
Journal:  Neurology       Date:  1995-07       Impact factor: 9.910

8.  Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.

Authors: 
Journal:  Lancet       Date:  1998-11-07       Impact factor: 79.321

9.  Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

Authors: 
Journal:  Lancet       Date:  1998-11-07       Impact factor: 79.321

10.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.

Authors: 
Journal:  Neurology       Date:  1993-04       Impact factor: 9.910
  10 in total
  1 in total

1.  [Noninflammatory pathogenesis of lesions in multiple sclerosis].

Authors:  M E Kornhuber
Journal:  Nervenarzt       Date:  2006-08       Impact factor: 1.214
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.